Global biosimilar market forecast to reach $99.28bn by 2024
Global market research and consulting organisation Infoholic Research has concluded that the global biosimilar drugs market will experience a compound...
Trending:
-
![]()
FDA to decide on Teva’s migraine treatment by September
-
![]()
Merck claims chemotherapy more effective when combined with its Keytruda
-
![]()
Esperion reports success from study to reduce LDL-C levels
-
![]()
Pharma Technology Focus – Issue 71
-
![]()
FDA certifies new drug for thrombocytopenia
-
![]()
Breakthroughs for haemophilia gene therapies
Expert commentary & analysis from GlobalData
EMA post-Brexit: will the UK become a second-tier state?
ASGCT 2018: does pricing allow fair access to gene-based therapies?
Is artificial intelligence the future of drug discovery?
Aimovig marks a new milestone for migraine
Most Read
Company releases
Upcoming Pharmaceutical Courses in June and July by NSF
NSF has announced a range of upcoming courses in June and July. Make sure you remember to take advantage of...
Pall Hosts Finding the Common Road to Quality for Single-Use Materials Webinar
Malvern Panalytical Releases New Zetasizer Pro And Zetasizer Ultra
Malvern Panalytical has introduced its new Zetasizer® Pro and Ultra systems.
PHAME Training for Pharmaceutical Experts
Gerresheimer Expands Production in Brazil
Gerresheimer has announced that is has expanded its production capabilities at its plastic primary packaging...
Company whitepapers
Best Practices and Lessons Learned from US Speciality Care
TemptimeZetasizer Pro and Zetasizer Ultra
Malvern PanalyticalABC Pharma for Healthcare Shipments
ABCPatch Pump Applications
Weibel CDSHierarchy for CAPA Effectiveness
NSF International, Pharma BiotechSuitability of HPMC Capsules for Pharmaceutical Applications
ACG Associated CapsulesSelf Administration with Injection Systems
HaselmeierCompany A-Z
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.
Projects
WuXi Biologics’ Biologics Manufacturing Facility, Dundalk, Ireland
In April 2018, China-based biologics services provider WuXi Biologics announced its plans to construct a new biologics drug substance manufacturing facility in Dundalk, Ireland.
Fresenius Kabi’s Pharmaceutical Manufacturing Facility Expansion, Melrose Park, Illinois
Mayne Pharma’s Oral Solid Dose Manufacturing Facility, Greenville, North Carolina
Aldevron GMP Plasmid Manufacturing Facility, Fargo, North Dakota, US
Datwyler’s Elastomer Components Manufacturing Facility, Middletown, Delaware
Clinical Trials
FDA to decide on Teva’s migraine treatment by September
Israel-based pharmaceutical company Teva has announced confirmation that the US Food and Drugs Administration (FDA) will make a decision on the company’s migraine treatment fremanezumab...
Merck claims chemotherapy more effective when combined with its Keytruda
FDA certifies new drug for thrombocytopenia
Breakthroughs for haemophilia gene therapies
FIT Biotech and Avacta announce positive results of pilot Affimer delivery study
Drug Development
FDA to decide on Teva’s migraine treatment by September
Israel-based pharmaceutical company Teva has announced confirmation that the US Food and Drugs Administration (FDA) will make a decision on the company’s migraine treatment fremanezumab...
Esperion reports success from study to reduce LDL-C levels
FDA certifies new drug for thrombocytopenia
Evotec signs cancer drug development alliance with Celgene
MIT team develops single-injection polymer vaccine for polio
Market Data
Global biosimilar market forecast to reach $99.28bn by 2024
Global market research and consulting organisation Infoholic Research has concluded that the global biosimilar drugs market will experience a compound annual growth rate (CAGR) of...
European Commission approves Sandoz’s biosimilar Zessly
Deals this week: Cipla, Takeda Pharmaceutical, Cadila Healthcare
Pfizer gets breakthrough status from FDA for cardiomyopathy drug
FDA reviews Sanofi’s application for type 1 diabetes drug
Technology
Beam receives gene-editing technology licence from Harvard
US start-up Beam Therapeutics has secured a worldwide licence from Harvard University to develop and commercialise a DNA base editing platform for precision genetic medicines.
Big data analyses animal studies’ predictions for human safety
Allen Institute launches 3D model of live human cell
XtalPi and Pfizer to develop AI software to identify new drugs
Bristol-Myers Squibb and Flatiron to collaborate on RWE